Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in Pediatric and Young Adult Relapsed/Refractory Malignancies
NCT03236857Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events up to 9 months, Number of Participants With Dose Limiting Toxicities and 4 more. Started Nov 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)neuroblastoma
Beyond the preview
Go deeper on NCT03236857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236857.